LC
IRWD icon

Lindbrook Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Lindbrook Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-326
Closed -$1.44K – 2863
2024
Q4 		$1.44K Sell
326
-149
-31% -$605 ﹤0.01% 2397
2024
Q3 		$1.96K Sell
475
-152
-24% -$817 ﹤0.01% 2351
2024
Q2 		$4.09K Sell
627
-339
-35% -$2.4K ﹤0.01% 2093
2024
Q1 		$8.41K Sell
966
-183
-16% -$2.22K ﹤0.01% 1659
2023
Q4 		$13.1K Buy
1,149
+875
+319% +$8.65K ﹤0.01% 1396
2023
Q3 		$2.64K Sell
274
-254
-48% -$2.49K ﹤0.01% 2025
2023
Q2 		$5.62K Buy
528
+281
+114% +$3.02K ﹤0.01% 1753
2023
Q1 		$2.6K Buy
247
+144
+140% +$1.61K ﹤0.01% 2130
2022
Q4 		$1.28K Hold
103
– – ﹤0.01% 2407
2022
Q3 		$1K Buy
+103
New +$1.17K ﹤0.01% 2364
2022
Q2 		– Sell
-42
Closed -$1K – 2615
2022
Q1 		$1K Buy
+42
New +$481 ﹤0.01% 2260

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Lindbrook Capital's IRWD Position: Q1 2025 in Review

Lindbrook Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 326 shares — an estimated $1.44K sold.

Lindbrook Capital first reported a position in IRWD in Q1 2022 and held it in 11 quarters. The position peaked at $13.1K in Q4 2023. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Lindbrook Capital reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 326 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $1.44K.
  • Lindbrook Capital first reported a position in Ironwood Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Lindbrook Capital's Ironwood Pharmaceuticals position peaked at $13.1K in Q4 2023.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.